Bli medlem
Bli medlem

Du är här

2014-04-15

Vitrolife AB (publ): Conference call interim report

Invitation to attend Vitrolife's conference call regarding
presentation of the interim report for the period January - March
2014. The presentation will be held in English.

Time: Wednesday, April 23, 2014 at 10.00 a.m. CET.

Registration can preferably be done in advance under the following
link:

https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=1...

or shortly before time of the conference starts on:

Sweden dial in number: +46 (0)8 5052 01 10
UK dial in number: +44 (0)20 7162 0077
Conference name: Vitrolife, conference ID: 944026

Vitrolife participants:
Thomas Axelsson, CEO
Mikael Engblom, CFO
The press release for Vitrolife's interim report will be released at
8.30 CET on the same day.

Before the conference call, slides will be available at the company
web page, http://www.vitrolife.com/en/Corporate/

A recorded version of the presentation will be available for seven
days on number

+46 (0)8 5052 0333 (Sweden) or 020 7031 4064 (UK), access code 944026.

Gothenburg, April 16, 2014
VITROLIFE AB (publ)

Contact:
Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release
in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. The information was submitted for
publication on April 16, 2014 at 08:30 a.m.

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international
medical device Group. Vitrolife Fertility
(http://www.vitrolife.com/en/Fertility/) product area develops,
produces and markets medical devices for assisted reproduction. Work
is also carried out to enable the use and handling of stem cells for
therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately
240 employees and the company's products are sold in almost 110
markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United
Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share
(http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX Stockholm
(http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE13469),
Small Cap.

_________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate
identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80
99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

-----------------------------------------------------------
http://news.cision.com/vitrolife-ab--publ-/r/conference-call-interim-rep...
http://mb.cision.com/Main/1031/9570060/233927.pdf

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.